Roche’s adjusted operating profit rose by a lower-than-expected 5% in 2025, due to the weakened US dollar, despite the ...

The FDA has granted breakthrough therapy designation to Biogen’s litifilimab for CLE, a chronic autoimmune skin condition.

AstraZeneca's investment coincides with China’s burgeoning presence in the pharmaceutical industry, driven by an uptick in innovative medicines R&D.

Sensorion has announced a $71.9m reserved offering through the issuance of 214,285,714 new ordinary shares at €0.28 per share to advance the development of its gene therapy pipeline.

This year, sales of Eliquis (apixaban) are projected to decline by 15.2% due to the loss of its European market exclusivity ...

Lilly and German biotech Seamless Therapeutics will develop recombinase-based treatments for hearing loss. In a move that ...

The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.

Insilico Medicine has entered a strategic partnership with Qilu Pharmaceutical to develop treatments for cardiometabolic diseases.

Real-world evidence (RWE) empowers payers and providers to make more informed, cost-effective treatment. Read more here: ...

Other countries in Europe to lose eliminated status include Armenia, Austria, Azerbaijan, Spain, and Uzbekistan. Sustained ...

Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted for review the supplemental biologics licence application (sBLA) submitted by the former for Leqembi Iqlik ...